← Home
📢 Press Releases
| Date | Press release |
|---|---|
| 2026-10-28 16:15:00 | Antero Midstream Announces Third Quarter 2026 Financial And Operating Results Denver, oct. 28, 2026 /prnewswire/ -- antero midstream corporation (nyse: am) (’antero midstream’ or the ’company’) today announced its third quarter 2026 financial and operating results. the relevant consolidated financial statements are included in antero midstream’s quarterly report on form 10-q for the three months ended september 30, 2026. |
| 2026-10-14 16:15:00 | Antero Midstream Announces Third Quarter 2026 Return Of Capital And Earnings Release Date And Conference Call Denver, oct. 14, 2026 /prnewswire/ -- antero midstream corporation (nyse: am) (’antero midstream’ or the ’company’) today announced that the board of directors of antero midstream declared a cash dividend of $0.225 per share for the third quarter of 2026. the company also repurchased approximately 1.3 million shares during the third quarter. |
| 2026-07-29 16:15:00 | Antero Midstream Announces Second Quarter 2026 Financial And Operating Results Denver, july 29, 2026 /prnewswire/ -- antero midstream corporation (nyse: am) (’antero midstream’ or the ’company’) today announced its second quarter 2026 financial and operating results. the relevant consolidated financial statements are included in antero midstream’s quarterly report on form 10-q for the three months ended june 30, 2026. |
| 2026-07-15 16:15:00 | Antero Midstream Announces Second Quarter 2026 Return Of Capital And Earnings Release Date And Conference Call Denver, july 15, 2026 /prnewswire/ -- antero midstream corporation (nyse: am) (’antero midstream’ or the ’company’) today announced that the board of directors of antero midstream declared a cash dividend of $0.225 per share for the second quarter of 2026. the company also repurchased approximately 0.4 million shares during the second quarter. |
| 2026-05-14 07:30:00 | Galmed Announces Results From First-in-man Pharmacokinetics Study Of Oral Formulation Of Aramchol Meglumine (am); 400mg Am Increases Bioavailability By ~500% In Comparison To Aramchol Free Acid (aa) 300mg Results from study am-001 mark a pivotal advance through the transition to a once daily lower 400mg dose of am enabling: production of gmp clinical batch for galmed’s upcoming clinical trials solidification and prolongation of aramchol’s ip protection potential reduction in drug cogs by ~50% improvement in patients’ convenience and compliance upon potential commercialization ramat-gan, israel, may 14, 2026 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) (’galmed’ or the ’company’), a clinical-stage biopharmaceutical company for liver disease and gi oncological therapeutics, announced today major milestone results from a phase 1 pk study in healthy subjects (study am-001). |
| 2026-04-29 16:15:00 |
|
| 2026-04-15 16:15:00 |
|
| 2026-02-11 16:15:00 |
|
| 2026-01-14 16:15:00 |
|
| 2025-12-17 07:00:00 |
|
| 2025-12-09 17:39:00 |
|
| 2025-12-09 07:52:00 |
|
| 2025-12-08 07:00:00 |
|
| 2025-10-29 16:15:00 |
|
| 2025-10-08 16:15:00 |
|
📰 Browse additional press releases for Antero Midstream Corp!
Sign up for free or log in🚀 Don’t miss "The Checklist Value Investor — A Smarter Way to Pick Stocks" — free!